Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes ; volume:15 ; number:1 ; day:20 ; month:12 ; year:2024 ; pages:1 ; date:12.2024
Nature Communications ; 15, Heft 1 (20.12.2024), 1, 12.2024

Classification: Recht

Creator: Grewal, Ramandip
Nguyen, Lena
Buchan, Sarah A.
Wilson, Sarah E.
Nasreen, Sharifa
Austin, Peter C.
Brown, Kevin A.
Fell, Deshayne B.
Gubbay, Jonathan B.
Schwartz, Kevin L.
Tadrous, Mina
Wilson, Kumanan
Kwong, Jeffrey C.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41467-024-55350-3

URN: urn:nbn:de:101:1-2503012122038.724358107547

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Grewal, Ramandip
Nguyen, Lena
Buchan, Sarah A.
Wilson, Sarah E.
Nasreen, Sharifa
Austin, Peter C.
Brown, Kevin A.
Fell, Deshayne B.
Gubbay, Jonathan B.
Schwartz, Kevin L.
Tadrous, Mina
Wilson, Kumanan
Kwong, Jeffrey C.
SpringerLink (Online service)

Other Objects (12)

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial

Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial

Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial

Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read and agree to the privacy policy for the collection of personal data.*

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Author Correction: Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Show object

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial

Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial

Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine

Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant

Clinical characteristics and booster vaccine effectiveness of the Omicron variant

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial

Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants

Related objects

Reset password